MCID: PRS012
MIFTS: 47

Pars Planitis

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pars Planitis

MalaCards integrated aliases for Pars Planitis:

Name: Pars Planitis 57 12 73 20 44 15 17 70
Posterior Cyclitis 12 32
Vitritis 20 70
Peripheral Retinal Inflammation 20
Uveitis, Intermediate 70
Intermediate Uveitis 20

Classifications:



External Ids:

Disease Ontology 12 DOID:12731
OMIM® 57 606177
ICD9CM 34 363.21
MeSH 44 D015868
NCIt 50 C34903
SNOMED-CT 67 193452008
ICD10 32 H30.2
MedGen 41 C0030593
UMLS 70 C0030593 C0042166 C0235812

Summaries for Pars Planitis

GARD : 20 Pars planitis is a disease of the eye that is characterized by inflammation of the narrowed area (pars plana) between the colored part of the eye (iris) and the choroid. This may lead to blurred vision; dark, floating spots in the vision; and progressive vision loss. As the condition advances, cataracts, retinal detachment, or macular edema (fluid within the retina) may develop. Pars planitis most often affects young men and is generally not associated with any other disease or symptoms (idiopathic); however, it can be associated with other autoimmune conditions such as multiple sclerosis and sarcoidosis. Treatment typically includes corticosteroid drugs, immunosuppressive medications, and/or surgery.

MalaCards based summary : Pars Planitis, also known as posterior cyclitis, is related to retinal vasculitis and intermediate uveitis. An important gene associated with Pars Planitis is HLA-A (Major Histocompatibility Complex, Class I, A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are hematopoietic system and immune system

Wikipedia : 73 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary sites... more...

More information from OMIM: 606177

Related Diseases for Pars Planitis

Diseases related to Pars Planitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
# Related Disease Score Top Affiliating Genes
1 retinal vasculitis 31.6 RBP3 CCR6
2 intermediate uveitis 31.6 IL2 HLA-DRB1 HLA-B CCR6
3 iridocyclitis 30.7 RBP3 HLA-B
4 cytomegalovirus retinitis 30.6 HLA-DRB1 HLA-B HLA-A
5 vogt-koyanagi-harada disease 30.3 HLA-DRB1 HLA-B HLA-A
6 uveitis 30.3 RBP3 IL2 IL1R1 IL1A HLA-B HLA-A
7 chorioretinitis 30.3 RBP3 IL2
8 hypopyon 30.2 RBP3 HLA-B
9 wells syndrome 30.0 IL2 IL1R1
10 htlv-1 associated myelopathy/tropical spastic paraparesis 30.0 HLA-DRB1 HLA-B HLA-A
11 tropical spastic paraparesis 30.0 IL2 HLA-B HLA-A
12 demyelinating disease 30.0 IL2 HLA-DRB1 CCR6
13 severe cutaneous adverse reaction 29.9 HLA-DRB1 HLA-B HLA-A
14 acquired immunodeficiency syndrome 29.8 IL2 HLA-B CCR6
15 rubella 29.8 IL2 HLA-DRB1 HLA-B HLA-A
16 panuveitis 29.7 RBP3 HLA-DRB1 HLA-B CCR6
17 iritis 29.7 RBP3 HLA-B CCR6
18 juvenile rheumatoid arthritis 29.6 IL2 IL1RN IL1R1 HLA-DRB1
19 narcolepsy 29.6 IL2 HLA-DRB1 HLA-B
20 acute disseminated encephalomyelitis 29.6 HLA-DRB1 HLA-B CCR6
21 posterior uveitis 29.5 RBP3 IL2 IL1A CCR6
22 crohn's disease 29.5 IL2 IL1A HLA-DRB1 CCR6
23 vitiligo-associated multiple autoimmune disease susceptibility 1 29.4 IL2 HLA-B CCR6
24 birdshot chorioretinopathy 29.4 RBP3 HLA-A CCR6
25 familial mediterranean fever 29.2 IL1RN IL1R1 IL1A HLA-A
26 myeloma, multiple 29.1 IL2 CD28 CD27 CCR6
27 spondyloarthropathy 1 29.1 IL1RN IL1R1 HLA-B CCR6
28 mycosis fungoides 29.1 IL2 CD28 CCR7 CCR6
29 graft-versus-host disease 29.0 IL2 IL1A HLA-DRB1 HLA-B HLA-A CD28
30 aphthous stomatitis 28.9 IL2 IL1RN IL1A HLA-DRB1 HLA-B HLA-A
31 psoriatic arthritis 28.9 IL2 IL1RN IL1A HLA-DRB1 HLA-B HLA-A
32 lymphoma, non-hodgkin, familial 28.9 IL2 HLA-A CD28 CD27 CCR7 CCR6
33 disease by infectious agent 28.9 IL2 IL1RN CD28 CCR6
34 human immunodeficiency virus type 1 28.9 IL2 IL1R1 HLA-B HLA-A CD28 CCR7
35 relapsing-remitting multiple sclerosis 28.8 IL2 IL1RN HLA-DRB1 CD28 CCR6
36 muckle-wells syndrome 28.8 IL1RN IL1R1 IL1A CCR6
37 eye disease 28.7 RBP3 IL2 IL1RN IL1R1 IL1A CCR6
38 alopecia areata 28.5 IL2 IL1RN IL1R1 IL1A HLA-DRB1 HLA-B
39 inflammatory bowel disease 28.4 IL2 IL1RN IL1R1 IL1A HLA-DRB1 HLA-B
40 multiple sclerosis 28.2 IL2 IL1RN IL1R1 HLA-DRB1 HLA-A CD28
41 sarcoidosis 1 28.2 IL2 IL1RN IL1A HLA-DRB1 HLA-A CD28
42 autoimmune disease 27.0 RBP3 IL2 IL1RN IL1R1 IL1A HLA-DRB1
43 macular retinal edema 10.8
44 retinal detachment 10.6
45 cataract 10.5
46 vasculitis 10.4
47 optic neuritis 10.3
48 neuritis 10.3
49 caplan's syndrome 10.3 HLA-DRB1 HLA-A
50 frontal fibrosing alopecia 10.3 HLA-B HLA-A

Graphical network of the top 20 diseases related to Pars Planitis:



Diseases related to Pars Planitis

Symptoms & Phenotypes for Pars Planitis

Clinical features from OMIM®:

606177 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Pars Planitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.61 CCR6 CCR7 CD27 CD28 HLA-A IL1A
2 immune system MP:0005387 9.28 CCR6 CCR7 CD27 CD28 HLA-A IL1A

Drugs & Therapeutics for Pars Planitis

Drugs for Pars Planitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3 glucocorticoids Phase 4
4 Anti-Inflammatory Agents Phase 4
5 Gastrointestinal Agents Phase 4
6 Antiemetics Phase 4
7 Antineoplastic Agents, Hormonal Phase 4
8 BB 1101 Phase 4
9 Hormone Antagonists Phase 4
10 Hormones Phase 4
11 Melanocyte-Stimulating Hormones Phase 4
12 Adrenocorticotropic Hormone Phase 4
13 beta-Endorphin Phase 4
14
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
15
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 3 67-73-2 6215
16
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
19
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
20
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
21
Mycophenolic acid Approved Phase 3 24280-93-1 446541
22
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
23
Adalimumab Approved, Experimental Phase 3 331731-18-1 16219006
24
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
25 triamcinolone acetonide Phase 3
26 Triamcinolone diacetate Phase 3
27 Triamcinolone hexacetonide Phase 3
28
protease inhibitors Phase 2, Phase 3
29 HIV Protease Inhibitors Phase 2, Phase 3
30 Antirheumatic Agents Phase 3
31 Interferon-beta Phase 3
32 Antiviral Agents Phase 3
33 interferons Phase 3
34 Methylprednisolone Acetate Phase 3
35 Antitubercular Agents Phase 3
36 Pharmaceutical Solutions Phase 3
37
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
40
Methotrexate Approved Phase 1, Phase 2 1959-05-2, 59-05-2 126941
41
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2 149436
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
43 Anti-Infective Agents Phase 2
44 Antibiotics, Antitubercular Phase 2
45 Anti-Bacterial Agents Phase 2
46 Antifungal Agents Phase 2
47 Immunosuppressive Agents Phase 1, Phase 2
48 Vitamin B9 Phase 1, Phase 2
49 Vitamin B Complex Phase 1, Phase 2
50 Folic Acid Antagonists Phase 1, Phase 2

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
2 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
3 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) Terminated NCT03656692 Phase 4 Acthar Gel
4 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
5 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
6 A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM) Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
7 Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial Completed NCT01092533 Phase 3 Myfortic;Decortin
8 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
9 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
10 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
11 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02746991 Phase 3 Sham Injection;FAI Insert
12 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
13 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
14 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
15 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
16 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
17 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
18 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
19 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Withdrawn NCT01103024 Phase 3
20 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
21 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
22 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
23 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
24 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
25 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
26 Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
27 A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis Terminated NCT02125266 Phase 1, Phase 2 V404
28 A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis Withdrawn NCT01905124 Phase 2 CF101;Placebo
29 A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
30 Combined Fluocinolone Acetonide Sustained Drug Delivery System Implantation and Phacoemulsification/Intraocular Lens Implantation in Patients With Severe Uveitis Completed NCT00570830
31 Influence of Macular Edema on Quality of Life in Patients With Non-infectious Intermediate Uveitis Completed NCT01314469
32 Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis Completed NCT02879084
33 MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis Completed NCT02952001 4mg CLS-TA Suprachoriodal Injection;Sham procedure
34 Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis : a Retrospective Study Completed NCT04219176
35 Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis Not yet recruiting NCT04126850

Search NIH Clinical Center for Pars Planitis

Cochrane evidence based reviews: pars planitis

Genetic Tests for Pars Planitis

Anatomical Context for Pars Planitis

MalaCards organs/tissues related to Pars Planitis:

40
Eye, Retina, Endothelial, Bone Marrow, Lung, Bone, Liver

Publications for Pars Planitis

Articles related to Pars Planitis:

(show top 50) (show all 1163)
# Title Authors PMID Year
1
The association of HLA class II with pars planitis. 61 57
11336946 2001
2
Pars planitis: clinical features and class II HLA associations. 57 61
10080220 1999
3
Long-term visual outcome and complications associated with pars planitis. 57 61
8510893 1993
4
Familial pars planitis. 57 61
6635352 1983
5
Long-term outcomes of Boston keratoprosthesis type I: the Chinese People's Liberation Army General Hospital experience. 61
33674425 2021
6
Bilateral acute retinal necrosis during treatment with alemtuzumab for multiple sclerosis. 61
33789493 2021
7
A New Retinal Detachment Treatment Model for Evaluation of Vitreous Tamponades. 61
32806983 2021
8
Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. 61
33666160 2021
9
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study. 61
33566264 2021
10
UVEITIS TREATED WITH DEXAMETHASONE IMPLANT. 61
32618834 2021
11
Necrotizing retinitis in a patient with syphilis: A case report. 61
33655916 2021
12
Immunotherapy-Resistant Vitreoretinal Metastatic Melanoma. 61
33796519 2021
13
Pathogenesis of ocular toxoplasmosis. 61
32717377 2021
14
Severe ocular and adnexal complications in dengue hemorrhagic fever: A report of 29 eyes. 61
33595487 2021
15
[Treatment of vascularized high-risk eyes with a Boston keratoprosthesis]. 61
33730307 2021
16
Bilateral hypopyon in syphilitic uveitis. 61
33437894 2021
17
Cluster of Post-Operative Endophthalmitis Caused by Acanthamoeba T10 Genotype - A First Report. 61
33201060 2021
18
Panuveitis in a patient with active Crohn's disease. 61
33541992 2021
19
Clinical features of childhood uveitis at a tertiary referral center in Southern Turkey. 61
33624176 2021
20
Clinical Course and Treatment Paradigms for JIA-related Uveitis and Pars Planitis Uveitis Using Precise Ocular Investigational Methods. 61
33607692 2021
21
An Atypical Presentation of Sympathetic Ophthalmia in an Intact Globe Following Mechanical Fall: A Case Report and Literature Review. 61
33669961 2021
22
Characterization of Gene Therapy Associated Uveitis Following Intravitreal Adeno-Associated Virus Injection in Mice. 61
33630023 2021
23
Non-infectious Intraocular Inflammation Following Intravitreal Anti-Vascular Endothelial Growth Factor Injection. 61
33631912 2021
24
Anterior chamber tap cytology in acute postoperative endophthalmitis: a case-control study. 61
33574032 2021
25
Spectral domain optical coherence tomography findings of patients with pars planitis and risk factors affecting visual acuity. 61
33559832 2021
26
Long-term outcomes following primary versus secondary Boston keratoprosthesis type 1 implantation. 61
33622700 2021
27
Retinoblastoma in an older Hispanic child masquerading as pars planitis: A case report. 61
33567900 2021
28
Driving in Fog without Headlight: Management of a Challenging Case of Presumed Ocular Toxoplasmosis. 61
31577475 2021
29
Unforeseen progressive outer retinal necrosis in a child following bone marrow transplant. 61
33408110 2021
30
Diffuse Unilateral Subacute Neuroretinitis Evolving With Submacular Granuloma. 61
31647685 2021
31
Intraocular solitary extramedullary plasmacytoma presenting as unilateral anterior and intermediate uveitis preceded by refractory glaucoma. 61
33516180 2021
32
Vitreoretinal Lymphoma: A Literature Review and Introduction of a New Diagnostic Method. 61
33481398 2021
33
Multimodal Imaging in AIDS-Related Ocular Cryptococcosis. 61
33628553 2021
34
A novel OCT signature in leukemic papillopathy masquerading as autoimmune or infectious uveitis. 61
33394161 2021
35
BILATERAL ENTEROCOCCUS FAECALIS ENDOPHTHALMITIS WITH MULTIPLE RECURRENCES. 61
29489562 2021
36
TNF-α Inhibitors for the Management of Intractable Corneal Melt: Report of Three Cases and Review of the Literature. 61
33399412 2021
37
HEMORRHAGIC OCCLUSIVE RETINAL VASCULITIS AFTER INTRACAMERAL VANCOMYCIN USE IN CATARACT SURGERY AFTER INTRAVENOUS EXPOSURE. 61
29474222 2021
38
Intraocular T-cell lymphoma metastasizing from a primary adrenal T-cell lymphoma: Case report. 61
33304580 2020
39
Bartonella henselae Neuroretinitis: A Rare Coinfection in POEMS Syndrome. 61
33389938 2020
40
Noninfectious endophthalmitis following intravitreal triamcinolone acetonide: clinical case and literature review. 61
32702307 2020
41
Clinical manifestations of intravitreal bortezomib injection. 61
33163689 2020
42
Belatacept associated - cytomegalovirus retinitis in a kidney transplant recipient: a case report and review of the literature. 61
33256663 2020
43
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study. 61
33294727 2020
44
Multi-Modal Imaging in Diffuse Subretinal Fibrosis With Uveitis Syndrome. 61
33394959 2020
45
Granulicatella adiacens endophthalmitis after phacoemulsification cataract surgery. 61
32818359 2020
46
The clinical spectrum of ocular bartonellosis: a retrospective study at a tertiary centre in Malaysia. 61
33191467 2020
47
Delayed-Onset Streptococcus intermedius Endophthalmitis Following Anti-Vascular Endothelial Growth Factor Intravitreal Injection. 61
33165298 2020
48
Clinical Presentation, Management, and Long-Term Outcome of Pars Planitis, Panuveitis, and Vogt-Koyanagi-Harada Disease in Children and Adolescents. 61
31444859 2020
49
Atypical bilateral acute retinal necrosis in a coronavirus disease 2019 positive immunosuppressed patient. 61
33225728 2020
50
Vitritis and Outer Retinal Abnormalities in a Patient with COVID-19. 61
33021846 2020

Variations for Pars Planitis

Expression for Pars Planitis

Search GEO for disease gene expression data for Pars Planitis.

Pathways for Pars Planitis

Pathways related to Pars Planitis according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.7 IL2 IL1RN IL1R1 IL1A HLA-DRB1 HLA-B
2
Show member pathways
13.64 IL2 IL1R1 IL1A CD28 CD27 CCR7
3
Show member pathways
13.47 IL2 IL1RN IL1R1 IL1A CD28 CD27
4
Show member pathways
13.2 IL2 IL1R1 IL1A CD28 CD27 CCR7
5
Show member pathways
12.98 IL2 IL1R1 IL1A CD28 CD27 CCR7
6
Show member pathways
12.44 IL2 IL1A HLA-DRB1 HLA-B HLA-A CD28
7
Show member pathways
12.39 IL2 IL1R1 IL1A HLA-DRB1 CD28
8
Show member pathways
12.37 IL2 IL1A HLA-DRB1 HLA-B HLA-A CD28
9
Show member pathways
12.34 IL2 IL1RN IL1R1 IL1A HLA-DRB1 HLA-B
10
Show member pathways
12.1 IL2 IL1A HLA-B HLA-A
11 12.01 IL1A HLA-B HLA-A
12 11.99 HLA-DRB1 HLA-B HLA-A
13 11.97 HLA-DRB1 HLA-B HLA-A CD28
14
Show member pathways
11.89 IL2 IL1R1 IL1A
15 11.87 IL2 IL1R1 IL1A
16 11.85 IL2 CD28 CCR7
17
Show member pathways
11.81 HLA-DRB1 HLA-A CD28
18 11.76 IL1R1 IL1A HLA-DRB1
19 11.72 IL1A HLA-DRB1 CD28
20
Show member pathways
11.7 IL1R1 CD28 CCR7
21 11.69 IL2 IL1R1 HLA-DRB1 HLA-B HLA-A
22
Show member pathways
11.68 IL2 IL1R1 HLA-DRB1 HLA-A
23 11.64 IL2 IL1R1 CCR6
24 11.46 IL1R1 IL1A CD28
25 11.4 IL1RN IL1R1 IL1A
26 11.12 IL2 IL1A HLA-DRB1
27 11.06 IL2 HLA-DRB1 CD28
28 11.04 HLA-B HLA-A
29 10.93 IL1R1 IL1A

GO Terms for Pars Planitis

Cellular components related to Pars Planitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.06 IL1RN IL1R1 HLA-DRB1 HLA-B HLA-A CD28
2 integral component of plasma membrane GO:0005887 9.8 IL1R1 HLA-DRB1 HLA-B HLA-A CD28 CD27
3 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DRB1 HLA-B HLA-A
4 external side of plasma membrane GO:0009897 9.43 IL1R1 HLA-DRB1 CD28 CD27 CCR7 CCR6
5 MHC class I protein complex GO:0042612 9.37 HLA-B HLA-A
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-DRB1 HLA-B HLA-A
7 cell surface GO:0009986 9.23 IL1R1 HLA-DRB1 HLA-B HLA-A CD28 CD27

Biological processes related to Pars Planitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 adaptive immune response GO:0002250 9.89 IL2 HLA-DRB1 HLA-B HLA-A
2 inflammatory response GO:0006954 9.86 IL1RN IL1R1 IL1A CCR7
3 T cell receptor signaling pathway GO:0050852 9.78 HLA-DRB1 HLA-A CD28
4 cytokine-mediated signaling pathway GO:0019221 9.78 IL2 IL1RN IL1R1 IL1A
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.76 IL2 CCR7 CCR6
6 interleukin-1-mediated signaling pathway GO:0070498 9.7 IL1RN IL1R1 IL1A
7 positive regulation of mitotic nuclear division GO:0045840 9.62 IL1A CD28
8 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.61 HLA-B HLA-A
9 inflammatory response to antigenic stimulus GO:0002437 9.6 IL1RN HLA-DRB1
10 positive regulation of T cell differentiation GO:0045582 9.58 IL2 CD27
11 interferon-gamma-mediated signaling pathway GO:0060333 9.58 HLA-DRB1 HLA-B HLA-A
12 dendritic cell chemotaxis GO:0002407 9.57 CCR7 CCR6
13 regulation of regulatory T cell differentiation GO:0045589 9.55 IL2 CD28
14 negative thymic T cell selection GO:0045060 9.54 CD28 CCR7
15 positive regulation of isotype switching to IgG isotypes GO:0048304 9.51 IL2 CD28
16 positive regulation of interferon-gamma production GO:0032729 9.5 IL2 IL1R1 HLA-A
17 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.49 HLA-B HLA-A
18 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.46 HLA-B HLA-A
19 positive regulation of dendritic cell chemotaxis GO:2000510 9.43 CCR7 CCR6
20 antigen processing and presentation GO:0019882 9.43 HLA-DRB1 HLA-B HLA-A
21 protection from natural killer cell mediated cytotoxicity GO:0042270 9.37 HLA-B HLA-A
22 positive regulation of T cell mediated cytotoxicity GO:0001916 9.33 HLA-DRB1 HLA-B HLA-A
23 immune response GO:0006955 9.32 IL2 IL1RN IL1R1 IL1A HLA-DRB1 HLA-B
24 detection of bacterium GO:0016045 9.13 HLA-DRB1 HLA-B HLA-A

Molecular functions related to Pars Planitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C-C chemokine binding GO:0019957 9.4 CCR7 CCR6
2 C-C chemokine receptor activity GO:0016493 9.37 CCR7 CCR6
3 chemokine receptor activity GO:0004950 9.32 CCR7 CCR6
4 interleukin-1 receptor binding GO:0005149 9.26 IL1RN IL1A
5 T cell receptor binding GO:0042608 9.16 HLA-DRB1 HLA-A
6 TAP binding GO:0046977 8.96 HLA-B HLA-A
7 peptide antigen binding GO:0042605 8.8 HLA-DRB1 HLA-B HLA-A

Sources for Pars Planitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....